6-Chloro-2-methyl-2H-indazol-5-amine CAS 1893125-36-4 Purity >98.0% (LCMS) Ensitrelvir (S-217622) Intermediate COVID-19

Short Description:

Name: 6-Chloro-2-methyl-2H-indazol-5-amine 

CAS: 1893125-36-4

Purity: >98.0% (LCMS) 

Appearance: Light Brown to Gray Solid Powder

Intermediate of Ensitrelvir (S-217622), COVID-19

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Product Detail

Related Products

Product Tags


Chemical Properties:

Chemical Name 6-Chloro-2-methyl-2H-indazol-5-amine
CAS Number 1893125-36-4
CAT Number RF-PI1506
Stock Status In Stock 
Molecular Formula C8H8ClN3
Molecular Weight 181.62
Brand Ruifu Chemical


Item Specifications
Appearance Light Brown to Gray Solid Powder
Purity / Analysis Method >98.0% (LCMS)
1 H NMR Spectrum Consistent With Structure
LCMS Consistent With Structure
Loss on Drying ≤1.00%
Total Impurities <2.00%
Test Standard Enterprise Standard
Usage Intermediate of Ensitrelvir (S-217622), COVID-19

Package & Storage:

Package: Bottle, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.





6-Chloro-2-methyl-2H-indazol-5-amine (CAS: 1893125-36-4) is an intermediate of Ensitrelvir (S-217622). Ensitrelvir by Shionogi & Co. is a highly effective antiviral drug that works just as well as Pfizer's Paxlovid. Oral Xocova (Ensitrelvir), which has the same mechanism of action as Pfizer’s Paxlovid (Nirmatrelvir+Ritonavir), differs in that it only needs to be taken once a day, while the therapeutic effectiveness of ensitrelvir does not seem to be inferior to Paxlovid. As a reminder, Nirmatrelvir is administered twice daily, together with the booster represented by Ritonavir. Ensitrelvir became the first Japanese domestic pill to treat COVID-19, third to be regulatorally approved in Japan; in February 2022.

  • Write your message here and send it to us